fluoxetine sold brand name prozac among others antidepressant selective serotonin reuptake inhibitor ssri used treatment major depressive disorder disorder ocd anxiety bulimia nervosa panic disorder premenstrual dysphoric also approved treatment major depressive disorder adolescents children years age also used treat premature fluoxetine taken common side effects include indigestion trouble sleeping sexual dysfunction loss appetite nausea diarrhea dry mouth rash serious side effects include serotonin syndrome mania seizures increased risk suicidal behavior people years old increased risk antidepressant discontinuation syndrome less likely occur fluoxetine antidepressants still happens many cases fluoxetine taken pregnancy associated significant increase congenital heart defects suggested fluoxetine therapy may continued breastfeeding used pregnancy antidepressants fluoxetine invented eli lilly company entered medical use world health organizations list essential available generic commonly prescribed medication united states million lilly also markets fluoxetine fixeddose combination olanzapine olanzapinefluoxetine fluoxetine frequently used treat major depressive disorder disorder ocd posttraumatic stress disorder ptsd bulimia nervosa panic disorder premenstrual dysphoric disorder also used cataplexy obesity alcohol well binge eating fluoxetine seems ineffective social anxiety studies support benefit children autism though tentative evidence benefit adult fluoxetine together fluvoxamine shown initial promise potential treatment reducing severity given fluoxetine approved treatment major depression children metaanalysis trials adults conclude fluoxetine modestly outperforms fluoxetine may less effective antidepressants high children adolescents moderatetosevere depressive disorder fluoxetine seems best treatment either without cognitive behavioural therapy although fluoxetine alone appear superior cbt alone research needed certain effect sizes small existing evidence dubious systematic review two original blindedcontrol trials used approve use fluoxetine children adolescents depression found control trials severely flawed demonstrate efficacy fluoxetine effective treatment disorder ocd also effective treating ocd children american academy child adolescent psychiatry state ssris including fluoxetine used firstline therapy children along cognitive behavioral therapy cbt treatment moderate severe efficacy fluoxetine treatment panic disorder demonstrated two randomized multicenter phase iii clinical trials enrolled patients diagnosed panic disorder without agoraphobia first trial subjects fluoxetinetreated arm free panic attacks end study vs placebo arm second trial fluoxetine treated patients free panic attacks end study vs placebo systematic review discussed seven trials compared fluoxetine placebo treatment bulimia nervosa six found statistically significant reduction symptoms vomiting binge however difference observed treatment arms fluoxetine psychotherapy compared psychotherapy alone fluoxetine used treat premenstrual dysphoric disorder condition individuals affective somatic symptoms monthly luteal phase taking fluoxetine mgd effective treating though doses mgd also prescribed fluoxetine considered firstline medication treatment impulsive aggression low fluoxetine reduced low intensity aggressive behavior patients intermittent aggressive disorder borderline personality fluoxetine also reduced acts domestic violence alcoholics history systematic review compared effects weight various doses fluoxetine mgd mgd mgd mgd obese overweight compared placebo dosages fluoxetine appeared contribute weight loss lead increased risk experiencing side effects dizziness drowsiness fatigue insomnia nausea period treatment however conclusions low certainty comparing review effects fluoxetine weight obese overweight adults antiobesity agents gel capsule receiving treatment authors could reach conclusive results due poor quality children adolescents fluoxetine antidepressant choice due tentative evidence favoring efficacy evidence supporting increased risk major fetal malformations resulting fluoxetine exposure limited although medicines healthcare products regulatory agency mhra united kingdom warned prescribers patients potential fluoxetine exposure first trimester organogenesis formation fetal organs cause slight increase risk congenital cardiac malformations furthermore association fluoxetine use first trimester increased risk minor fetal malformations observed one however systematic review metaanalysis studies published journal obstetrics gynaecology canada concluded apparent increased risk fetal cardiac malformations associated maternal use fluoxetine recently shown also depressed women deferred ssri therapy pregnancy therefore probably reflects ascertainment bias overall women treated fluoxetine first trimester pregnancy appear increased risk major fetal per fda infants exposed ssris late pregnancy may increased risk persistent pulmonary hypertension newborn limited data support risk fda recommends physicians consider tapering ssris fluoxetine third review recommended fluoxetine firstline ssri lactation stating fluoxetine viewed lesspreferred ssri breastfeeding mothers particularly newborn infants mothers consumed fluoxetine sertraline often preferred ssri pregnancy due relatively minimal fetal exposure observed safety profile side effects observed fluoxetinetreated persons clinical trials incidence least twice common fluoxetinetreated persons compared received placebo pill include abnormal dreams abnormal ejaculation anorexia anxiety asthenia diarrhea dizziness dry mouth dyspepsia fatigue flu syndrome impotence insomnia decreased libido nausea nervousness pharyngitis rash sinusitis somnolence sweating tremor vasodilation fluoxetine considered stimulating ssris prone causing insomnia also appears prone ssris producing dermatologic reactions eg urticaria hives rash itchiness sexual dysfunction including loss libido erectile dysfunction lack vaginal lubrication anorgasmia commonly encountered adverse effects treatment fluoxetine ssris early clinical trials suggested relatively low rate sexual dysfunction recent studies investigator actively inquires sexual problems suggest incidence pharmacovigilance risk assessment committee european medicines agency recommended packaging leaflets selected ssris snris amended include information regarding possible risk persistent sexual following european assessment safety review health canada could neither confirm rule causal link long lasting rare cases recommended healthcare professionals inform patients potential risk longlasting sexual dysfunction despite discontinuation fluoxetines longer halflife makes less common develop antidepressant discontinuation syndrome following cessation therapy especially compared antidepressants shorter halflives although gradual dose reductions recommended antidepressants shorter halflives tapering may necessary antidepressant exposure including fluoxetine associated shorter average duration pregnancy three days increased risk preterm delivery lower birth weight g lower apgar scores increase congenital heart defects among children whose mothers prescribed fluoxetine fluoxetine use first trimester associated increase septal heart october fda added black box warning antidepressant drugs regarding use fda included adults aged statistical analyses conducted two independent groups fda experts found increase suicidal ideation behavior children adolescents increase suicidality age group suicidality slightly decreased older statistically significantly lower older analysis criticized donald klein noted suicidality suicidal ideation behavior necessarily good surrogate marker suicide still possible unproven antidepressants may prevent actual suicide increasing february food drug administration fda ordered update warnings based statistical evidence twenty four trials risk events increased two percent four percent relative placebo september joseph wesbecker killed eight people injured twelve committing relatives victims blamed actions prozac medication begun taking month prior incident set chain lawsuits public lawyers began using prozac justify abnormal behaviors eli lilly accused enough warn patients doctors adverse effects described activation years prior less data fluoxetine antidepressants whole fda combine results trials antidepressants psychiatric indications obtain statistically significant results considered separately fluoxetine use children increased odds suicidality adults decreased odds suicidality approximately study published may found fluoxetine likely increase overall suicidal behavior patients n fluoxetine suicidal events compared psychotherapy group combined treatment similarly analysis conducted uk mhra found increase suiciderelated events reaching statistical significance children adolescents fluoxetine compared ones placebo according mhra data fluoxetine change rate selfharm adults statistically significantly decreased suicidal ideation fluoxetine affect electrical currents heart muscle cells use coordinate contraction specifically potassium currents ito iks repolarise cardiac action certain circumstances lead prolongation qt interval measurement made electrocardiogram reflecting long takes heart electrically recharge heartbeat fluoxetine taken alongside drugs prolong qt interval susceptibility long qt syndrome small risk potentially lethal abnormal heart rhythms torsades de study completed found fluoxetine alter qt interval clinically meaningful effects cardiac action overdose frequent adverse effects nervous system effects gastrointestinal effects effects contraindications include prior treatment within past weeks depending maois phenelzine tranylcypromine due potential serotonin use also avoided known hypersensitivities fluoxetine ingredients formulation use concurrently receiving pimozide thioridazine also advised case short term administration codeine pain management advised monitor adjust dosage codeine might provide sufficient analgesia fluoxetine opioid treatment required oxycodone use monitored since oxycodone metabolized cytochrome cyp enzyme system fluoxetine paroxetine potent inhibitors means combinations codeine oxycodone fluoxetine antidepressant may lead reduced cases use dextromethorphancontaining cold cough medications fluoxetine advised due fluoxetine increasing serotonin levels well fact fluoxetine cytochrome inhibitor causes dextromethorphan metabolized normal rate thus increasing risk serotonin syndrome potential side effects patients taking nsaids antiplatelet drugs anticoagulants fatty acids vitamin e garlic supplements must careful taking fluoxetine ssris sometimes increase bloodthinning effects fluoxetine norfluoxetine inhibit many isozymes cytochrome system involved drug metabolism potent inhibitors also chief enzyme responsible metabolism mild moderate inhibitors vivo fluoxetine norfluoxetine significantly affect activity also inhibit activity pglycoprotein type membrane transport protein plays important role drug transport metabolism hence pglycoprotein substrates loperamide may central effects extensive effect bodys pathways drug metabolism creates potential interactions many commonly used use also avoided receiving serotonergic drugs monoamine oxidase inhibitors tricyclic antidepressants methamphetamine amphetamine mdma triptans buspirone ginseng dextromethorphan dxm linezolid tramadol reuptake inhibitors ssris due potential serotonin syndrome develop fluoxetine may also increase risk opioid overdose instances part due inhibitory effect cytochrome similar fluoxetine effect metabolization dextromethorphan may cause medications like oxycodone metabolized normal rate thus increasing risk serotonin syndrome well resulting increased concentration oxycodone blood may lead accidental overdose study examined health insurance claims million americans began taking oxycodone using ssris found patients taking paroxetine fluoxetine higher risk overdosing oxycodone using also potential interaction highly proteinbound drugs due potential fluoxetine displace said drugs plasma vice versa hence increasing serum concentrations either fluoxetine offending fluoxetine selective serotonin reuptake inhibitor ssri appreciably inhibit norepinephrine dopamine reuptake therapeutic doses however delay reuptake serotonin resulting serotonin persisting longer released large doses rats shown induce significant increase synaptic norepinephrine thus dopamine norepinephrine may contribute antidepressant action fluoxetine humans supratherapeutic doses effect may mediated receptors inhibited higher concentrations fluoxetine increases concentration circulating allopregnanolone potent gabaa receptor positive allosteric modulator norfluoxetine primary active metabolite fluoxetine produces similar effect allopregnanolone levels brains additionally fluoxetine norfluoxetine modulators actions may clinically addition fluoxetine found act agonist potency greater citalopram less fluvoxamine however significance property fully fluoxetine also functions channel blocker anoctamin calciumactivated chloride number ion channels including nicotinic acetylcholine receptors receptors also known inhibited similar fluoxetine shown inhibit acid sphingomyelinase key regulator ceramide levels derives ceramide unclear fluoxetine exerts effect mood suggested fluoxetine elicits antidepressant effect inhibiting serotonin reuptake synapse binding reuptake pump neuronal increase serotonin availability enhance time leads downregulation presynaptic receptors associated improvement passive stress tolerance delayed downstream increase expression brainderived neurotrophic factor may contribute reduction negative affective norfluoxetine desmethylfluoxetine metabolites fluoxetine also act serotonin reuptake inhibitors increasing duration action prolonged exposure fluoxetine changes expression genes involved myelination process shapes brain connectivity contributes symptoms psychiatric disorders regulation genes involved myelination partially responsible longterm therapeutic benefits chronic ssri bioavailability fluoxetine relatively high peak plasma concentrations reached hours highly bound plasma proteins mostly albumin fluoxetine metabolized liver isoenzymes cytochrome system including role metabolism fluoxetine may clinically important great genetic variability function enzyme among people responsible converting fluoxetine active metabolite drugs also potent inhibitors extremely slow elimination fluoxetine active metabolite norfluoxetine body distinguishes antidepressants time fluoxetine norfluoxetine inhibit metabolism fluoxetine elimination halflife increases days single dose days longterm similarly halflife norfluoxetine longer days longterm therefore concentration drug active metabolite blood continues grow first weeks treatment steady concentration blood achieved four moreover brain concentration fluoxetine metabolites keeps increasing least first five weeks major depressive disorder onset antidepressant action may felt early full benefit current dose patient receives realized least month following ingestion example one study median time achieving consistent response likewise complete excretion drug may take several weeks first week treatment discontinuation brain concentration fluoxetine decreases blood level norfluoxetine four weeks treatment discontinuation level registered end first treatment week seven weeks discontinuation norfluoxetine still detectable fluoxetine norfluoxetine may quantitated blood plasma serum monitor therapy confirm diagnosis poisoning hospitalized person assist medicolegal death investigation blood plasma fluoxetine concentrations usually range μgl persons taking drug antidepressant effects μgl survivors acute overdosage μgl victims fatal overdosage norfluoxetine concentrations approximately equal parent drug chronic therapy may substantially less following acute overdosage since requires least weeks metabolite achieve work eventually led discovery fluoxetine began eli lilly company collaboration bryan molloy ray known time antihistamine diphenhydramine shows antidepressantlike properties compound structurally similar diphenhydramine taken starting point molloy fellow eli lilly chemist klaus schmiegel synthesized series dozens hoping find derivative inhibiting serotonin reuptake another eli lilly scientist david wong proposed retest series vitro reuptake serotonin norepinephrine dopamine using technique developed neuroscientist solomon test showed compound later named fluoxetine potent selective inhibitor serotonin reuptake first article fluoxetine published year later given official chemical name fluoxetine eli lilly company gave brand name prozac february dista products company division eli lilly company filed investigational new drug application us food drug administration fda fluoxetine appeared belgian market us fda gave final approval december month later eli lilly began marketing prozac annual sales us reached million within worldwide sales eventually reached peak billion lilly tried several product line extension strategies including extended release formulations paying clinical trials test efficacy safety fluoxetine premenstrual dysphoric disorder rebranding fluoxetine indication sarafem approved fda following recommendation advisory committee invention using fluoxetine treat pmdd made richard wurtman mit patent licensed startup interneuron turn sold defend prozac revenue generic competition lilly also fought fiveyear multimilliondollar battle court generic company barr pharmaceuticals protect patents fluoxetine lost cases lineextension patents sarafem opening fluoxetine generic manufacturers starting lillys patent expired august generic drug competition decreased lillys sales fluoxetine within two investment bank projected annual sales sarafem could reach sales sarafem reached year lilly sold assets connected drug galen holdings small irish pharmaceutical company specializing dermatology womens health sales force tasked gynecologists offices analysts found deal sensible since annual sales sarafem made material financial difference galen bringing sarafem market harmed lillys reputation quarters diagnostic category pmdd controversial since first proposed lillys role retaining appendix dsmivtr discussions got way lilly criticized inventing disease order make innovating rather seeking ways continue making money existing also criticized fda groups concerned womens health marketing sarafem aggressively first launched campaign included television commercial featuring harried woman grocery store asks million prescriptions generic fluoxetine filled united making thirdmost prescribed antidepressant sertraline million prescriptions fluoxetine filled united along amitriptyline commonly prescribed first antidepressant adolescents aged years fluoxetine detected aquatic ecosystems especially north growing body research addressing effects fluoxetine among ssris exposure nontarget aquatic one first studies addressed detail potential effects fluoxetine aquatic wildlife research concluded exposure environmental concentrations little risk aquatic systems hazard quotient approach applied risk however also stated need research addressing sublethal consequences fluoxetine specifically focusing study species sensitivity behavioural responses endpoints modulated serotonin fluoxetine similar several ssris induces reproductive behavior shellfish concentrations low parts per since number studies reported fluoxetineinduced impacts number behavioural physiological endpoints inducing antipredator fielddetected concentrations however review ecotoxicology fluoxetine concluded time consensus ability environmentally realistic dosages affect behaviour wildlife could environmentally realistic concentrations fluoxetine alters insect emergence richmond et al find low concentrations accelerates emergence diptera unusually high concentrations discernable several common plants known absorb several crops tested redshaw et al find cauliflower absorbs large amounts stem leaf head wu et al find lettuce spinach also absorb detectable amounts carter et al find radish raphanus sativus ryegrass lolium perenne wu et al find soybean glycine max absorb wu tested tissues soybean showed low contrast various reinhold et al find duckweeds high uptake fluoxetine show promise bioremediation contaminated water especially lemna minor landoltia ecotoxicity organisms involved aquaculture well fluoxetine affects aquacultured invertebrates vertebrates inhibits soil microbes including large antibacterial applications see uses campaign governor florida disclosed one candidates lawton chiles depression resumed taking fluoxetine leading political opponents question fitness serve beginning april fluoxetine became one four antidepressant drugs faa permitted pilots authorization aviation medical examiner permitted antidepressants sertraline zoloft citalopram celexa escitalopram four remain antidepressants permitted faa december sertraline citalopram escitalopram antidepressants permitted easa medical certification january antibacterial effect described environmental effects could applied multiresistant biotypes crop bacterial diseases bacterial aquaculture glucocorticoid receptordefective zebrafish mutant danio rerio reduced exploratory behavior fluoxetine rescued normal exploratory demonstrates relationships glucocorticoids fluoxetine exploration fluoxetine antinematode choy et al finds effect due interference certain transmembrane fluoxetine effective treating anxiety related behaviours separation anxiety dogs especially used supplementation behaviour httpsenwikipediaorgwikifluoxetine